Brinsupri

Brensocatib · Insmed Netherlands B.V.
PRIME AUTHORISED IN THE EU

What Brinsupri is used for

Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.

Approved use, as published by the European Medicines Agency.

What the labels mean

  • PRIME: a priority medicine that the EMA supported early because it may meet an unmet need.

Key facts

Brand
Brinsupri
Active substance
Brensocatib
Disease area
Bronchiectasis; Lung Diseases
ATC code
R03
Marketing authorisation holder
Insmed Netherlands B.V.
Authorised in the EU since
2025

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Brinsupri used for?

Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.

What is the active substance in Brinsupri?

Brinsupri contains Brensocatib.

Who makes Brinsupri?

The EU marketing authorisation holder is Insmed Netherlands B.V..

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.